A graphic depicting Carlos Campoy, a Latino man with light hair, being announced to the Zymeworks board of directors.
Graphic credited to Mónica Hernández/AL DÍA.

Zymeworks Inc. gains Latino new board member

The biotech company has appointed Carlos Campoy to serve on its board of directors.


Strengthening Latino Market

September 14th, 2023

Latino Board Experience

September 5th, 2023

Talented Latinos in Tech

August 31st, 2023

Growing the Biz in Latam

August 29th, 2023

A new CEO at Kraft Heinz

August 18th, 2023

Latina at the helm of NPR

August 18th, 2023


Zymeworks Inc., a clinical-stage biotechnology company that works to create new, multipurpose biotherapeutics, has announced the appointment of Carlos Campoy to its board of directors, effective June 30.

In addition to his appointment to the board of directors, he has also been appointed to the audit committee, and the nominating and corporate governance committee of the board of directors.

Campoy succeeds Dr. Natalie Sacks, who steps down from the position on June 30, following a 6-year tenure as board director.

“Carlos’ extensive global experience in financial leadership positions in the pharmaceutical and biotechnology industries over twenty-five years makes him a valuable addition to the Zymeworks board of directors,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks, in a statement.

“He is a skillful, thoughtful, and performance-driven financial executive with a successful track record in leading culturally diverse organizations through complex transformational changes in the U.S. and internationally, and I look forward to working with him on the board of directors,” he continued.

Campoy's career in the life sciences industry began with Eli Lily & Company in 1996, serving for 18 years in numerous different senior leadership positions internationally in places, such as the U.S., Latin America, Japan, and Europe.

From 2018 to 2019, Campoy served as the Chief Financial Officer at Alder Biopharmaceuticals, and held the same position at CytomX Therapeutics from 2020 to 2022.

“I’m very pleased to have the opportunity to join the board of directors at Zymeworks at such an exciting time for the company,” said Campoy. 

“I look forward to leveraging my financial and operating experience in the pharmaceutical and biotechnology industries to support Zymeworks’ future efforts in clinical development and commercialization of novel medicines for patients with difficult-to-treat cancers. Additionally, I am also committed to supporting a culture of diversity and individual fulfillment,” he concluded.

Campoy earned his Bachelor's degree in Management from Faculdade C.C. Administracao de Tupa in Brazil, and his MBA in Finance and Decision Information Systems from Indiana University.


  • Join the discussion! Leave a comment.

  • or
  • to comment.

  • Join the discussion! Leave a comment.

  • or
  • to comment.
00:00 / 00:00
Ads destiny link